While reporting financial results for the fourth quarter on Friday, biopharmaceutical company ANI Pharmaceuticals, Inc. (ANIP) raised its adjusted earnings and revenue guidance for the full-year 2025.
For fiscal 2025, the company now projects adjusted earnings in a range of $6.98 to $7.35 per share on net revenues between $818 million and $843 million.
Previously, the company expected adjusted earnings in the range of $6.27 to $6.62 per share on net revenues between $768 million and $793 million.
On average, eight analysts polled expect the company to report earnings of $6.51 per share on revenues of $791.48 million for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.